CN1328538A - 对视黄醛衍生物x(rxr)受体具有选择性活性的2,4－戊二烯酸衍生物 - Google Patents

对视黄醛衍生物x(rxr)受体具有选择性活性的2,4－戊二烯酸衍生物 Download PDF

Info

Publication number
CN1328538A
CN1328538A CN99813787A CN99813787A CN1328538A CN 1328538 A CN1328538 A CN 1328538A CN 99813787 A CN99813787 A CN 99813787A CN 99813787 A CN99813787 A CN 99813787A CN 1328538 A CN1328538 A CN 1328538A
Authority
CN
China
Prior art keywords
compound
formula
carbon atom
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99813787A
Other languages
English (en)
Chinese (zh)
Inventor
V·武利贡达
K·Y·曾
J·瓦苏德范
R·A·钱德拉拉特纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of CN1328538A publication Critical patent/CN1328538A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN99813787A 1998-10-01 1999-09-20 对视黄醛衍生物x(rxr)受体具有选择性活性的2,4－戊二烯酸衍生物 Pending CN1328538A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,950 1998-10-01
US09/164,950 US6147224A (en) 1998-10-01 1998-10-01 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors

Publications (1)

Publication Number Publication Date
CN1328538A true CN1328538A (zh) 2001-12-26

Family

ID=22596791

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99813787A Pending CN1328538A (zh) 1998-10-01 1999-09-20 对视黄醛衍生物x(rxr)受体具有选择性活性的2,4－戊二烯酸衍生物

Country Status (16)

Country Link
US (1) US6147224A (https=)
EP (2) EP1117628B1 (https=)
JP (1) JP2002526516A (https=)
KR (2) KR20010075457A (https=)
CN (1) CN1328538A (https=)
AR (1) AR020691A1 (https=)
AT (1) ATE254593T1 (https=)
AU (1) AU757932B2 (https=)
BR (1) BR9914256A (https=)
CA (1) CA2346034A1 (https=)
DE (1) DE69912973T2 (https=)
ES (1) ES2207339T3 (https=)
NZ (1) NZ510528A (https=)
TW (1) TW580494B (https=)
WO (1) WO2000020370A1 (https=)
ZA (1) ZA200102635B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105308026A (zh) * 2013-07-09 2016-02-03 东曹株式会社 具有金刚烷基的环状吖嗪化合物、制造方法、以及以该化合物作为构成成分的有机电致发光元件
CN109310769A (zh) * 2016-03-10 2019-02-05 Io治疗公司 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
TR200200507T2 (tr) 1999-08-27 2002-10-21 Ligand Pharmaceuticals Inc Androjen reseptörü modülatör bileşikleri ve metotları
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
AU7586600A (en) * 1999-09-14 2001-04-17 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
WO2002076941A2 (en) * 2001-03-27 2002-10-03 Circagen Pharmaceutical Histone deacetylase inhibitors
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6388105B1 (en) * 2001-09-27 2002-05-14 Allergan Sales, Inc. Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
WO2003099272A1 (en) * 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
WO2004046104A2 (en) 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US6683092B1 (en) 2003-04-09 2004-01-27 Allergan, Inc. [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en) * 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
BRPI0616454A2 (pt) 2005-09-30 2011-06-21 Vitae Pharmaceuticals, Inc. métodos de tratamento de cáncer
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
WO2017075607A1 (en) 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of pxr agonists and thyroid hormones
KR20180121983A (ko) 2016-03-10 2018-11-09 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
IL304970A (en) * 2017-11-17 2023-10-01 Io Therapeutics Inc Processes for the preparation of retinoids specific for the retinoid X receptor
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
MX2024006978A (es) 2021-12-07 2024-07-19 Io Therapeutics Inc Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826760D0 (en) * 1988-11-16 1988-12-21 Wellcome Found Pesticides
DE69224660C5 (de) * 1991-12-18 2010-06-02 The Salk Institute For Biological Studies, La Jolla Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen
DE10199033I2 (de) * 1992-04-22 2003-01-09 Ligand Parmaceuticals Inc Retinoid-x Rezeptor selektive Verbindungen
JPH08511027A (ja) * 1993-01-11 1996-11-19 リガンド・ファーマシューティカルズ・インコーポレーテッド レチノイドｘレセプターに対して選択的な活性を有する化合物、およびレチノイドｘレセプターによって媒体されたプロセスの調節手段
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
ES2133798T3 (es) * 1994-08-10 1999-09-16 Hoffmann La Roche Ligandos del receptor x del acido retinoico.
IL116259A (en) * 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
CA2233888A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
AU762492B2 (en) * 1999-03-08 2003-06-26 Basilea Pharmaceutica Ag Retinoid antagonists and use thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105308026A (zh) * 2013-07-09 2016-02-03 东曹株式会社 具有金刚烷基的环状吖嗪化合物、制造方法、以及以该化合物作为构成成分的有机电致发光元件
US9812652B2 (en) 2013-07-09 2017-11-07 Tosoh Corporation Cyclic azine compound having adamantyl group, production method, and organic electroluminescent device containing it as constituent component
CN105308026B (zh) * 2013-07-09 2018-12-21 东曹株式会社 具有金刚烷基的环状吖嗪化合物、制造方法、以及以该化合物作为构成成分的有机电致发光元件
CN109310769A (zh) * 2016-03-10 2019-02-05 Io治疗公司 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗
CN109310769B (zh) * 2016-03-10 2022-07-05 Io治疗公司 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗

Also Published As

Publication number Publication date
DE69912973T2 (de) 2004-07-22
TW580494B (en) 2004-03-21
US6147224A (en) 2000-11-14
WO2000020370A1 (en) 2000-04-13
ATE254593T1 (de) 2003-12-15
AR020691A1 (es) 2002-05-22
HK1039477A1 (en) 2002-04-26
JP2002526516A (ja) 2002-08-20
AU757932B2 (en) 2003-03-13
KR20060118367A (ko) 2006-11-23
NZ510528A (en) 2003-04-29
EP1388534A3 (en) 2004-02-25
CA2346034A1 (en) 2000-04-13
EP1388534A2 (en) 2004-02-11
BR9914256A (pt) 2001-07-03
EP1117628B1 (en) 2003-11-19
EP1117628A1 (en) 2001-07-25
KR20010075457A (ko) 2001-08-09
ZA200102635B (en) 2002-10-18
AU6051399A (en) 2000-04-26
DE69912973D1 (de) 2003-12-24
ES2207339T3 (es) 2004-05-16

Similar Documents

Publication Publication Date Title
CN1328538A (zh) 对视黄醛衍生物x(rxr)受体具有选择性活性的2,4－戊二烯酸衍生物
CN1102573C (zh) 具有类视色素拮抗剂或类视色素反相激动剂类型生物活性的芳基或杂芳基取代的3,4－二氢蒽和芳基或杂芳基取代的苯并[1,2－g]－色－3－烯、苯并[1,2 －g]－硫色－3－烯以及苯并[1,2－g]－1,2－二氢喹啉衍生物
CN1025332C (zh) 含二氢苯并噻喃基团的酚酯与对苯二酸酯的制备方法
CN1117070C (zh) 具有视黄酸衍生物类生物活性的四氢萘、苯并二氢吡喃、二氢苯并噻喃和1,2,3,4－四氢喹啉羧酸的芳基或杂芳基酰胺
JP4052668B2 (ja) レチノイド様生物学的活性を有する２，４−ペンタジエン酸誘導体
CN1080117C (zh) 用具有rxr类视色素受体激动剂活性的化合物治疗患肿瘤的哺乳动物
DE69808065T2 (de) Trisubstituierte phenyl derivate mit retinoid agonist, antagonist oder inversagonist biologischer aktivität
CN1176248A (zh) 受限的9－顺－视黄酸类
CN1211180A (zh) 用具有RARα受体特异性或选择性活性的化合物治疗的方法
CN1121374C (zh) 新的三烯类视黄酸化合物及方法
CN1144091A (zh) 具有视网膜样活性的化合物
CN1038092A (zh) 苯酚类或苯甲酸类的四氢化萘酯的制备方法
US6093838A (en) Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
JP3491635B2 (ja) ジヒドロナフタレン誘導体化合物およびその化合物を有効成分とする薬剤
US7019034B2 (en) Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
WO2001070662A2 (en) 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
NO880910L (no) Fremgangsmaate ved fremstilling av chromonderivater.
US6388105B1 (en) Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
CN1656088A (zh) 具有细胞色素p450rai抑制活性的取代性苯丙二氢呋喃衍生物
CN1063438C (zh) 链烯基-苯甲酰胍衍生物及其制备和用途
CN101050179A (zh) 2,3,4,5－四取代的苯丙烯类衍生物及其制备方法和用途
US6620963B1 (en) TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
HK1018939A (en) Methods of treatment with compounds having rara receptor specific or selective activity
HK1039477B (en) 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
HK1020188A (en) Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids having retinoid-like biological activity

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ALLERGAN INC.

Free format text: FORMER OWNER: ALLERGAN SALES, INC.

Effective date: 20040702

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20040702

Address after: California, USA

Applicant after: ALLERGAN, Inc.

Address before: California, USA

Applicant before: Allergan Sales, INC.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication